# Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma

> **NCT03980171** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Peter MacCallum Cancer Centre, Australia** · enrollment: 50 (actual)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** Obinutuzumab
- **DRUG:** Venetoclax
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT03980171
- **Lead sponsor:** Peter MacCallum Cancer Centre, Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-08-19
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2024-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03980171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03980171, "Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03980171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*